MacroGenics provides update on flotetuzumab program in acute myeloid leukemia
MacroGenics announced that it plans to advance the development of flotetuzumab, its investigational bispecific CD123 x CD3 DART® molecule, in patients with primary refractory acute myeloid leukemia, a difficult-to-treat patient population. July 17, 2019